APYX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
APYX is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some bullish long-term support from recent analyst upgrades and strong revenue growth, but profitability is still negative and the technical trend is weak. Given the user's impatient style and lack of an optimal-entry mindset, this is better treated as a hold rather than an immediate buy.
APYX is oversold in the short term, with RSI_6 at 13.089, which can signal a rebound attempt. However, the MACD histogram is negative and expanding, showing downside momentum is still active. Moving averages are converging, suggesting a possible inflection, but the current price of 3.33 is below the pivot at 3.746 and below resistance levels at 4.075 and 4.278, so the chart is not yet confirming a sustained uptrend. Short-term pattern data suggests only modest upside potential over the next day/week/month.
Recent analyst actions are supportive: Craig-Hallum raised its price target to $6 from $5 and kept a Buy rating, while BTIG upgraded the stock to Buy with a $6 target. Both firms cited strong quarterly execution, early momentum in the Ayon launch, GLP-1-related demand for skin tightening, international expansion, and improving visibility toward profitability. Revenue in the latest quarter grew 34.75% YoY, which is a meaningful growth signal.
There was no news in the recent week, so there is no immediate event-driven catalyst in the feed. Net income remains negative at -1.299 million and EPS fell to -0.03, showing profitability is still not established. Gross margin also slipped slightly to 62.61%. Insider and hedge fund activity is neutral, and there is no recent congress trading data to add conviction.
Latest quarter: 2025/Q4. Revenue increased to 19.164 million, up 34.75% YoY, which is the clearest strength in the financials. However, net income dropped to -1.299 million and EPS declined to -0.03, so the company is still unprofitable. Gross margin was 62.61%, down slightly YoY, indicating decent but slightly weakening profitability quality. Overall, growth is improving faster than earnings.
Wall Street sentiment has turned more positive recently. Craig-Hallum raised its target to $6 and kept Buy, and BTIG upgraded the stock to Buy with a $6 target. The pros view is that APYX has improving growth momentum, expanding geographic opportunities, and a path toward sustainable profitability. The main con view is that earnings are still negative and the market has not yet shown a decisive long-term trend confirmation.
